Symbiotec Pharmalab, a pharmaceutical company specializing in steroid and hormone active pharmaceutical ingredients, is advancing two major expansions to enhance its manufacturing capabilities: the launch of an injectable facility for dual-chamber vials (DCVs) and the establishment of a biomanufacturing hub. Anil Satwani, Managing Director, Symbiotec Pharmalab, outlined the expansions at the DCAT Member Company Announcement Forum at DCAT Week.  

Symbiotec is set to commission its advanced injectable DCV facility in Indore, Central India this month (April 2025). The production unit, equipped with an isolator-based filling line, will enable the manufacturing of DCVs that house freeze-dried drug powder in the bottom chamber and diluent in the upper chamber to enable sterile drug reconstitution at the point of administration. 

The company has invested $50 million in the new facility, which will have annual output of approximtely 20 million DCVs and accommodate a product range of 1 mL to 12 mL SKUs. The facility sits on six acres with room for expansion.  

In addition to its injectable facility, Symbiotec is also establishing a biomanufacturing hub in Indore, Central India. Set to be commissioned this month (April 2025), this hub will focus on end-to-end sustainable fermentation-based manufacturing for pharmaceuticals, alternate proteins, nutraceuticals, and bio-actives. The company is investing $40 million in the facility, and the facility will have capacity (Phase I of the facility) of 4 x 100 KL fermenters. For sustainability, the facility will also apply zero liquid dischard technology.